Although the study was small, the investigators believe it provides proof of principle for the usefulness of cell-free DNA to prognose and monitor glioblastomas.
The company has collected initial evidence for an algorithmic method to predict immunotherapy response, and is studying its technology in treatment monitoring.
The companies will use Foundation Medicine's FoundationOne CDx test as the baseline to define a set of unique variants that the codeveloped assays will monitor.
The company said it has seen progress in efforts to get FDA approval for its tissue and liquid biopsy tests as data continues to accumulate for pan-cancer utility.
In PNAS this week: tRNA fragment signature for chronic lymphocytic leukemia, genomic sites sensitive to ultraviolet radiation in melanocytes, and more.
